Scotti Luciana, Ishiki Hamilton Mitsugu, Duarte Marcelo Cavalcante, Oliveira Tiago Branquinho, Scotti Marcus T
Postgraduate Program in Natural Products and Synthetic Bioactive, Federal University of Paraíba, João Pessoa, PB, Brazil.
Teaching and Research Management - University Hospital, Federal University of Paraíba, João Pessoa, PB, Brazil.
Methods Mol Biol. 2018;1800:327-345. doi: 10.1007/978-1-4939-7899-1_16.
Current therapeutic strategies entail identifying and characterizing a single protein receptor whose inhibition is likely to result in the successful treatment of a disease of interest, and testing experimentally large libraries of small molecule compounds "in vitro" and "in vivo" to identify promising inhibitors in model systems and determine if the findings are extensible to humans. This highly complex process is largely based on tests, errors, risk, time, and intensive costs. The virtual computational study of compounds simulates situations predicting possible drug linkages with multiple protein target atomic structures, taking into account the dynamic protein inhibitor, and can help identify inhibitors efficiently, particularly for complex drug-resistant diseases. Some discussions will relate to the potential benefits of this approach, using HIV-1 and Plasmodium falciparum infections as examples. Some authors have proposed a virtual drug discovery that not only identifies efficient inhibitors but also helps to minimize side effects and toxicity, thus increasing the likelihood of successful therapies. This chapter discusses concepts and research of bioactive multitargets related to toxicology.
当前的治疗策略包括识别和表征单一蛋白质受体,抑制该受体可能成功治疗相关疾病,并在“体外”和“体内”对大量小分子化合物库进行实验测试,以在模型系统中识别有前景的抑制剂,并确定研究结果是否适用于人类。这个高度复杂的过程很大程度上基于测试、错误、风险、时间和高昂成本。对化合物的虚拟计算研究模拟预测与多个蛋白质靶标原子结构可能存在药物联系的情况,同时考虑动态蛋白质抑制剂,有助于高效识别抑制剂,特别是对于复杂的耐药性疾病。将以HIV-1和恶性疟原虫感染为例,讨论这种方法的潜在益处。一些作者提出了虚拟药物发现,不仅能识别有效的抑制剂,还有助于将副作用和毒性降至最低,从而增加成功治疗的可能性。本章讨论与毒理学相关的生物活性多靶点的概念和研究。